Skip to main navigation

Home
Technology
- Product Details
- HIFU Technology
Physicians
- Prostate Cancer Management
- Clinical Information
Patients
Company

Menu

Home
Technology
- Product Details
- HIFU Technology
Physicians
- Prostate Cancer Management
- Clinical Information
Patients
Company

FocalTherics™ - Investor Relations

Annual Reports

Investor Relations

Overview
News & Events
- News
- Events & Presentations
Financial Information
Stock Information
Corporate Governance
Investor Resources
- Contact Us
- Email Alerts

2025 Annual Report Thumbnail

2025 Annual Report

2024 Annual Report

2024 Annual Report

2023 Annual Report

2023 Annual Report

2022 Annual Report

2022 Annual Report

2021 Annual Report

2021 Annual Report

2020 Annual Report

2020 Annual Report

2019 Annual Report

2019 Annual Report

2018 Annual Report

2018 Annual Report

2017 Annual Report thumbnail

2017 Annual Report

2016 Annual Report

2016 Annual Report

Current page 1
Page 2
Page 3
Next page
Last page

Investor Contact

Louisa Smith

Gilmartin Group

investor.relations@focalone.com

EDAP TMS SA

investor.relations@focalone.com

Get Updates And Stay Connected

Get New Updates Directly To Your Inbox.

Email Address* Required

Focal One® - HIFU Prostate Tissue Ablation

Focal One^® has received regulatory clearance and is marketed in the United States, Europe, Canada, Korea, Russia, Brazil and other countries. In the United States, Focal One^® is indicated for the ablation of prostate tissue. Focal One^® is a registered trademark of EDAP TMS.

Discover More

FocalTherics Information

P: +1(512) 832-7956
E: investor.relations@focalone.com
A: 4410 El Camino Real, # 150,
Los Altos, CA 94022

EDAP TMS S.A., the issuer of record for the Company's publicly traded securities, is evolving its corporate brand to FocalTherics to better reflect its focused therapeutic ultrasound strategy and long-term growth vision. While the Company will continue to operate under its legal name, EDAP TMS S.A., it now does business as FocalTherics across its investor and corporate communications. This brand transition aligns the Company's identity with its expanding innovation portfolio while maintaining continuity, transparency, and regulatory compliance for shareholders. All historical filings, disclosures, and governance materials remain attributable to EDAP TMS S.A., ensuring clarity and consistency throughout this evolution.